Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)
Open Access
- 23 December 2020
- journal article
- research article
- Published by Elsevier BV in EClinicalMedicine
- Vol. 31, 100693
- https://doi.org/10.1016/j.eclinm.2020.100693
Abstract
No abstract availableFunding Information
- American Cancer Society
- National Cancer Institute
This publication has 49 references indexed in Scilit:
- Six years afterActa Radiologica, 2012
- Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe SepsisThe New England Journal of Medicine, 2012
- What have we learnt from Vioxx?BMJ, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- Osteonecrosis of the Jaw and BisphosphonatesThe New England Journal of Medicine, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialThe New England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionThe New England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryThe New England Journal of Medicine, 2005
- Expecting the Unexpected — Drug Safety, Pharmacovigilance, and the Prepared MindThe New England Journal of Medicine, 2004
- Valvular Heart Disease Associated with Fenfluramine–PhentermineThe New England Journal of Medicine, 1997